GB2551453B - Nanocarrier delivery system for hydrophobic substances - Google Patents
Nanocarrier delivery system for hydrophobic substances Download PDFInfo
- Publication number
- GB2551453B GB2551453B GB1713495.8A GB201713495A GB2551453B GB 2551453 B GB2551453 B GB 2551453B GB 201713495 A GB201713495 A GB 201713495A GB 2551453 B GB2551453 B GB 2551453B
- Authority
- GB
- United Kingdom
- Prior art keywords
- delivery system
- hydrophobic substances
- nanocarrier delivery
- nanocarrier
- hydrophobic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MYPI2015700198A MY197126A (en) | 2015-01-23 | 2015-01-23 | Nanocarrier delivery system for hydrophobic substances |
PCT/MY2016/050004 WO2016118001A1 (en) | 2015-01-23 | 2016-01-21 | Nanocarrier delivery system for hydrophobic substances |
Publications (3)
Publication Number | Publication Date |
---|---|
GB201713495D0 GB201713495D0 (en) | 2017-10-04 |
GB2551453A GB2551453A (en) | 2017-12-20 |
GB2551453B true GB2551453B (en) | 2020-09-09 |
Family
ID=56417447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB1713495.8A Active GB2551453B (en) | 2015-01-23 | 2016-01-21 | Nanocarrier delivery system for hydrophobic substances |
Country Status (5)
Country | Link |
---|---|
CN (1) | CN107427471B (en) |
AU (1) | AU2016209724B2 (en) |
GB (1) | GB2551453B (en) |
MY (1) | MY197126A (en) |
WO (1) | WO2016118001A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019094625A1 (en) * | 2017-11-09 | 2019-05-16 | Nexien Biopharma, Inc. | Methods and compositions for parenteral administration of cannabidiol in the treatment of convulsive disorders |
EP3849515A1 (en) * | 2018-09-11 | 2021-07-21 | Memorial Sloan Kettering Cancer Center | Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use |
CN112180079B (en) * | 2020-09-25 | 2024-04-19 | 上海睿康生物科技有限公司 | Stable liposome particle and application thereof in immune turbidimetry detection |
CN113318217A (en) * | 2021-06-02 | 2021-08-31 | 厦门大学 | BTZ-TPGS compound, nano preparation, preparation and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003053407A1 (en) * | 2001-12-19 | 2003-07-03 | Research Development Foundation | Liposomal delivery of vitamin e based compounds |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101569607B (en) * | 2009-06-16 | 2011-02-16 | 中国药科大学 | Di-demethoxycurcumin precursor liposome and preparation method thereof |
-
2015
- 2015-01-23 MY MYPI2015700198A patent/MY197126A/en unknown
-
2016
- 2016-01-21 GB GB1713495.8A patent/GB2551453B/en active Active
- 2016-01-21 AU AU2016209724A patent/AU2016209724B2/en active Active
- 2016-01-21 CN CN201680017476.3A patent/CN107427471B/en active Active
- 2016-01-21 WO PCT/MY2016/050004 patent/WO2016118001A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003053407A1 (en) * | 2001-12-19 | 2003-07-03 | Research Development Foundation | Liposomal delivery of vitamin e based compounds |
Non-Patent Citations (5)
Title |
---|
FU J.Y et al., "Tumor Regression After Systemic Administration of Tocotrienol Entrapped in Tumor-Targeted Vesicles", Journal of Controlled Release, (20090000), vol. 140, pages 95 - 99, * |
FU J.Y. et al., "Novel Tocotrienol-Entrapping Vesicles can Eradicate Solid Tumors After Intravenous Administration", Journal of Controlled Release, (20110000), vol. 154, pages 20 - 26, * |
FU J.Y. et al., "Tumor-Targeted Niosome as Novel Carrier for Intravenous Administration of Tocotrienol", Asian Journal of Pharmaceutical Sciences, vol. 11, (20160000), pages 79 - 80, (20151125), * |
GOPINATH D. et al., "Ascorbyl Palmitate Vesciles (Aspasomes): Formation, Characterization and Applications", International Journal of Pharmaceutics, (20040000), vol. 271, pages 95 - 113, * |
VARSHOSAZ J. et al., "Niosomes of Ascorbic Acid and a-Tocopherol in the Cerebral Ishemia-Reperfusion Model in Male Rats", BioMed Research International, (20140000), vol. 2014, no. art. ID 816103, * |
Also Published As
Publication number | Publication date |
---|---|
MY197126A (en) | 2023-05-26 |
AU2016209724A1 (en) | 2017-09-14 |
CN107427471A (en) | 2017-12-01 |
GB201713495D0 (en) | 2017-10-04 |
GB2551453A (en) | 2017-12-20 |
WO2016118001A1 (en) | 2016-07-28 |
CN107427471B (en) | 2020-07-31 |
AU2016209724B2 (en) | 2021-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB201802837D0 (en) | Awrosol delivery system | |
ZA201807048B (en) | Medical delivery system | |
IL250659A0 (en) | Sensor systems for drug delivery devices | |
EP3349670A4 (en) | Releasable delivery system | |
EP3725349C0 (en) | Improved systems for medicine delivery | |
SG10202012083YA (en) | Liquid delivery system | |
PT3314091T (en) | Grout delivery system | |
HK1254624A1 (en) | Delivery systems for controlled drug release | |
EP3283752C0 (en) | Fluid delivery system | |
HK1250370A1 (en) | Bortezomib-based delivery system | |
HK1251159A1 (en) | Improved nanoparticle delivery systems | |
GB201407614D0 (en) | Content delivery system | |
HUE057487T2 (en) | Drug delivery system | |
GB201715590D0 (en) | Delivery system | |
GB2559712B (en) | Solid state delivery system | |
GB2551453B (en) | Nanocarrier delivery system for hydrophobic substances | |
IL246874A0 (en) | Drug delivery system | |
IL247106A0 (en) | Substance delivery system | |
IL275664A (en) | Drug delivery system | |
GB201517654D0 (en) | Object delivery system | |
GB201514495D0 (en) | Self-emulsifying Nanosuspensions as Drug Delivery Systems | |
GB2559449B (en) | Hypoallergic drug delivery system | |
IL256994A (en) | Transdermal delivery system | |
IL256995A (en) | Transdermal delivery system | |
GB201721699D0 (en) | Delivery system |